Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

Provencio, Mariano; Nadal, Ernest; González-Larriba, José-Luis; Martinez-Martí, Alex; Bernabé, Reyes; Bosch-Barrera, Joaquim; Casal‐Rubio, Joaquín; Calvo, Virginia; Insa, Amelia; Ponce, Santiago; Reguart, Noemı́; Castro, Javier de; Mosquera, Joaquín; Cobo-Dols, Manuel; Aguilar, Andrés; Vivanco, Guillermo López; Camps, Carlos; López-Castro, Rafael; Morán, Teresa; Barneto, I.; Rodríguez-Abreu, Delvys; Serna‐Blasco, Roberto; Benítez, Raquel; Rosa, C. Aguado de la; Palmero, R.; Hernando-Trancho, Florentino; Martín-López, Javier; Cruz-Bermúdez, Alberto; Massutí, Bartomeu; Romero, Atocha

doi:10.1056/nejmoa2215530

Cited by 203 publications

(158 citation statements)

References 18 publications

Supporting

Mentioning

148

Contrasting

Unclassified

Order By: Relevance

“…Patients could benefit from the treatment of toripalimab regardless of PD-L1 tumor expression levels. In this study, 78% of all enrolled patients had squamous NSCLC, which is higher than expected based on previously reported data in patients with NSCLC . This difference might partly be caused by the exclusion of a higher proportion of patients with nonsquamous NSCLC and EGFR alterations in Chinese patients.…”

Section: Discussioncontrasting

confidence: 66%

“…Randomized clinical trials have evaluated perioperative checkpoint inhibition in patients with resectable NSCLC. The phase 2, NADIM II randomized clinical trial, revealed that the addition of perioperative nivolumab demonstrated a higher pathological complete response rate and improved survival compared with chemotherapy alone. In the KEYNOTE-671 study, the addition of pembrolizumab to neoadjuvant chemotherapy plus adjuvant pembrolizumab led to significant improvements in event-free survival (HR, 0.58 [95% CI, 0.46-0.72]) in patients with stage II to IIIB NSCLC compared with those who received chemotherapy alone.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Lu,

Zhang,

et al. 2024

JAMA

View full text Add to dashboard Cite

ImportanceAdjuvant and neoadjuvant immunotherapy have improved clinical outcomes for patients with early-stage non–small cell lung cancer (NSCLC). However, the optimal combination of checkpoint inhibition with chemotherapy remains unknown.ObjectiveTo determine whether toripalimab in combination with platinum-based chemotherapy will improve event-free survival and major pathological response in patients with stage II or III resectable NSCLC compared with chemotherapy alone.Design, Setting, and ParticipantsThis randomized clinical trial enrolled patients with stage II or III resectable NSCLC (without EGFR or ALK alterations for nonsquamous NSCLC) from March 12, 2020, to June 19, 2023, at 50 participating hospitals in China. The data cutoff date for this interim analysis was November 30, 2022.InterventionsPatients were randomized in a 1:1 ratio to receive 240 mg of toripalimab or placebo once every 3 weeks combined with platinum-based chemotherapy for 3 cycles before surgery and 1 cycle after surgery, followed by toripalimab only (240 mg) or placebo once every 3 weeks for up to 13 cycles.Main Outcomes and MeasuresThe primary outcomes were event-free survival (assessed by the investigators) and the major pathological response rate (assessed by blinded, independent pathological review). The secondary outcomes included the pathological complete response rate (assessed by blinded, independent pathological review) and adverse events.ResultsOf the 501 patients randomized, 404 had stage III NSCLC (202 in the toripalimab + chemotherapy group and 202 in the placebo + chemotherapy group) and 97 had stage II NSCLC and were excluded from this interim analysis. The median age was 62 years (IQR, 56-65 years), 92% of patients were male, and the median follow-up was 18.3 months (IQR, 12.7-22.5 months). For the primary outcome of event-free survival, the median length was not estimable (95% CI, 24.4 months-not estimable) in the toripalimab group compared with 15.1 months (95% CI, 10.6-21.9 months) in the placebo group (hazard ratio, 0.40 [95% CI, 0.28-0.57], P &lt; .001). The major pathological response rate (another primary outcome) was 48.5% (95% CI, 41.4%-55.6%) in the toripalimab group compared with 8.4% (95% CI, 5.0%-13.1%) in the placebo group (between-group difference, 40.2% [95% CI, 32.2%-48.1%], P &lt; .001). The pathological complete response rate (secondary outcome) was 24.8% (95% CI, 19.0%-31.3%) in the toripalimab group compared with 1.0% (95% CI, 0.1%-3.5%) in the placebo group (between-group difference, 23.7% [95% CI, 17.6%-29.8%]). The incidence of immune-related adverse events occurred more frequently in the toripalimab group. No unexpected treatment-related toxic effects were identified. The incidence of grade 3 or higher adverse events, fatal adverse events, and adverse events leading to discontinuation of treatment were comparable between the groups.Conclusions and RelevanceThe addition of toripalimab to perioperative chemotherapy led to a significant improvement in event-free survival for patients with resectable stage III NSCLC and this treatment strategy had a manageable safety profile.Trial RegistrationClinicalTrials.gov Identifier: NCT04158440

show abstract

Section: Discussioncontrasting

confidence: 66%

Section: Introductionmentioning

confidence: 99%

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Lu,

Zhang,

et al. 2024

JAMA

View full text Add to dashboard Cite

show abstract

“…

Neoadjuvant immunotherapy is safe before surgery in head and neck squamous cell carcinoma. Is it time to challenge the standard-of-care?The incorporation of neoadjuvant immunotherapy is rapidly changing the standard-of-care for multiple cancers, including neoadjuvant immunotherapy alone for melanoma, 1 rectal cancer, 2 colon cancer, 3 and cutaneous squamous cell carcinoma 4 or immunotherapy with chemotherapy for less immunoresponsive tumor types such as nonsmall cell lung cancer 5,6 and triple-negative breast cancer. 7 The sci-Neil D. Gross reports institutional research funding from Regeneron

…”

mentioning

confidence: 99%

“…Given relatively low responses rates to single agent neoadjuvant immunotherapy in HNSCC, 17 it is likely that combination therapy, with associated increased toxicity, may be preferred and necessary to broadly implement a neoadjuvant approach similar to what has been observed in non-small cell lung cancer. 5,6,18 The risk-benefit ratio may also be quite different depending on the site of disease in HNSCC. For example, the tolerance for risk with neoadjuvant immunotherapy is likely greater among HPV-negative HNSCC patients than HPV-positive patients, where the prognosis is excellent.…”

mentioning

confidence: 99%

“…The incorporation of neoadjuvant immunotherapy is rapidly changing the standard‐of‐care for multiple cancers, including neoadjuvant immunotherapy alone for melanoma, 1 rectal cancer, 2 colon cancer, 3 and cutaneous squamous cell carcinoma 4 or immunotherapy with chemotherapy for less immunoresponsive tumor types such as non–small cell lung cancer 5,6 and triple‐negative breast cancer 7 . The scientific rationale for the application of immunotherapy before surgery is strong, 8 and neoadjuvant may be preferable to adjuvant use 1 .…”

mentioning

confidence: 99%

See 1 more Smart Citation

Neoadjuvant immunotherapy is safe before surgery in head and neck squamous cell carcinoma. Is it time to challenge the standard‐of‐care?

Gross,

Seiwert

2024

Cancer

View full text Add to dashboard Cite

show abstract

Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC

Zhou,

Li,

et al. 2024

JAMA Netw Open

View full text Add to dashboard Cite

ImportanceNeoadjuvant therapy combining programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors with platinum-based chemotherapy has demonstrated significant improvement in pathologic response and survival rates among patients with resectable non–small cell lung cancer (NSCLC). However, it remains controversial whether PD-1 blockade therapy given before and after surgery (neoadjuvant-adjuvant treatment) is associated with better outcomes than when given only before surgery (neoadjuvant-only treatment).ObjectiveTo compare the efficacy and safety associated with neoadjuvant-adjuvant anti–PD-1 and anti–PD-L1 therapy with neoadjuvant-only anti–PD-1 and anti–PD-L1 therapy for patients with resectable NSCLC.Data SourcesA systematic search was conducted across databases including PubMed, Embase, and the Cochrane Library, as well as major oncology conferences, through July 31, 2023.Study SelectionRandomized clinical trials comparing neoadjuvant-adjuvant or neoadjuvant-only PD-1 and PD-L1 inhibitor therapy vs chemotherapy alone for patients with resectable NSCLC were selected.Data Extraction and SynthesisFollowing the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline, 2 authors independently extracted data. Hazard ratios (HRs) and 95% CIs for event-free survival (EFS) and overall survival (OS) were extracted and then pooled through the generic inverse-variance methods. Relative risks (RRs) for treatment-related adverse events (TRAEs) were derived via the Mantel-Haenszel method. Using chemotherapy as a common comparator, indirect comparisons between neoadjuvant-adjuvant immunotherapy and neoadjuvant-only immunotherapy were conducted using frequentist methods. A random or fixed model was used based on intertrial heterogeneity identified through the Cochran Q test.Main Outcomes and MeasuresThe primary outcome was EFS, with secondary outcomes including OS and TRAEs.ResultsThe study encompassed 4 trials of neoadjuvant-adjuvant immunotherapy and 1 trial of neoadjuvant-only immunotherapy, involving 2385 patients. Direct meta-analysis revealed significant improvements in EFS for both neoadjuvant-adjuvant and neoadjuvant-only immunotherapy compared with chemotherapy alone. In indirect meta-analysis, the addition of adjuvant immunotherapy to neoadjuvant immunotherapy was not associated with improved EFS (HR, 0.90; 95% CI, 0.63-1.30; P = .59) or OS (HR, 1.18; 95% CI, 0.73-1.90; P = .51) compared with neoadjuvant-only immunotherapy. Moreover, the incidence of any grade of TRAEs significantly increased with the addition of adjuvant immunotherapy (RR, 1.08; 95% CI, 1.00-1.17; P = .04).Conclusions and RelevanceThis meta-analysis suggests that adding PD-1 or PD-L1 inhibitors in the adjuvant phase to neoadjuvant treatment with PD-1 or PD-L1 inhibitors and chemotherapy may not improve survival outcomes for patients with resectable NSCLC and may be associated with increased adverse events. Future validation of these findings is warranted through head-to-head randomized clinical trials.

show abstract

Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

Cited by 203 publications

References 18 publications

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer

Neoadjuvant immunotherapy is safe before surgery in head and neck squamous cell carcinoma. Is it time to challenge the standard‐of‐care?

Neoadjuvant-Adjuvant vs Neoadjuvant-Only PD-1 and PD-L1 Inhibitors for Patients With Resectable NSCLC

Contact Info

Product

Resources

About